2 feb. 2013

Publicaciones conjuntas de los grupos de CliNK

Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.
Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66

KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression.
Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C.

Front Immunol. 2012;3:289

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7

Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity.
Moraru M, Cisneros E, Gómez-Lozano N, de Pablo R, Portero F, Cañizares M, Vaquero M, Roustán G, Millán I, López-Botet M, Vilches C.

J Immunol. 2012 May 1;188(9):4412-20.

The NF-kappaB member p65 controls glutamine metabolism through miR-23a..
Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempé D, Lecellier CH, Villalba M.

Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56.

Publicaciones del Grupo de Alberto Anel

Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.
De Miguel D, Basanez G, Sánchez D, Galán-Malo P, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L.

Mol Pharm. 2013 Jan 18. [Epub ahead of print]

Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity.
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187. doi: 10.3389/fimmu.2012.00187. Epub 2012 Jul 5.

Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: reactive oxygen species generation and inactive shortened SOD1 isoform implications.
Aguiló JI, Iturralde M, Monleón I, Iñarrea P, Pardo J, Martínez-Lorenzo MJ, Anel A, Alava MA.

Chem Biol Interact. 2012 Jun 25;198(1-3):18-28. doi: 10.1016/j.cbi.2012.05.001. Epub 2012 May 16.

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L, Marzo I, Anel A, Naval J.

Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2. Review.


APO2L/TRAIL: new insights in the treatment of autoimmune disorders.
Anel A, Martinez-Lostao L.

Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. Review.


Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency.
Bernardo I, Mancebo E, Aguiló I, Anel A, Allende LM, Guerra-Vales JM, Ruiz-Contreras J, Serrano A, Talayero P, de la Calle O, Gonzalez-Santesteban C, Paz-Artal E.

Haematologica. 2011 Aug;96(8):1195-203. doi: 10.3324/haematol.2011.041301. Epub 2011 May 5.

Publicaciones del Grupo de Julián Pardo

Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein.
Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.
Cancer Res. 2013 Jan 1;73(1):139-49.

Blinking effect and the use of quantum dots in single molecule spectroscopy.
Rombach-Riegraf V, Oswald P, Bienert R, Petersen J, Domingo MP, Pardo J, Gräber P, Galvez EM.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):260-4.

Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.
Aporta A, Arbues A, Aguilo JI, Monzon M, Badiola JJ, de Martino A, Ferrer N, Marinova D, Anel A, Martin C, Pardo J.

PLoS One. 2012;7(9):e45213.

Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis.
Domingo MP, Colmenarejo C, Martínez-Lostao L, Müllbacher A, Jarne C, Revillo MJ, Delgado P, Roc L, Meis JF, Rezusta A, Pardo J, Gálvez EM.

Diagn Microbiol Infect Dis. 2012 May;73(1):57-64.

Protein oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL.
Ospina A, Lagunas-Martínez A, Pardo J, Carrodeguas JA.

FEBS Lett. 2011 Oct 3;585(19):2935-42.

Course of infection with the emergent pathogen Brucella microti 
in immunocompromised mice.
Jiménez de Bagüés MP, de Martino A, Quintana JF,Alcaraz A,Pardo J.

Infect Immun. 2011 Oct;79(10):3934-9.

MAGUKs, scaffolding proteins at cell junctions, are substrates of different proteases during apoptosis.
Ivanova S, Gregorc U, Vidergar N, Javier R, Bredt DS, Vandenabeele P, Pardo J, Simon MM, Turk V, Banks L, Turk B.

Cell Death Dis. 2011 Jan 20;2:e116.

Mouse granzyme K has pro-inflammatory potential.
Joeckel LT, Wallich R, Martin P, Sanchez-Martinez D, Weber FC, Martin SF, Borner C, Pardo J, Froelich C, Simon MM.

Cell Death Differ. 2011 Jul;18(7):1112-9.

Perforin rapidly induces plasma membrane phospholipid flip-flop.
Metkar SS, Wang B, Catalan E, Anderluh G, Gilbert RJ, Pardo J, Froelich CJ.

PLoS One. 2011;6(9):e24286.

Publicaciones del Grupo de Isabel Marzo y Javier Naval

Direct interaction of Bax and Bak with Bcl-2 Homology domain-3 (BH3)-only proteins in living cells revealed by fluorescence complementation.
Vela L, Gonzalo O, Naval J, Marzo I.

J Biol Chem. 2013 Jan 2. [Epub ahead of print]

Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.
Carreira M, Calvo-Sanjuán R, Sanaú M, Marzo I, Contel M.

Organometallics. 2012 Aug 27;31(16):5772-5781.

Cytotoxic hydrophillic iminpphosphorane coordination compounds of d8 metals. Studies of their interaction with DNA and HSA.
Carreira M, Calvo-Sanjuán, R, Sanaú, M, Zhao, X, Magliozzo, RS, Marzo, I, Contel, M

J Inorg Biochem. 2012 Nov;116:204-14.

Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold.
Galán-Malo P, Vela L, Gonzalo O, Calvo-Sanjuán R, Gracia-Fleta L, Naval J, Marzo I.

Toxicol Appl Pharmacol. 2012 Feb 1;258(3):384-93.

Bortezomib resistance in a myeloma cell line is associated to PSM5 overexpression and polyploidy.
Balsas P, Galán-Malo P, Marzo I, Naval J.

Leuk Res. 2012 Feb;36(2):212-8.

Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.
Vela L, Contel M, Palomera L, Azaceta G, Marzo I.

J Inorg Biochem. 2011 Oct;105(10):1306-1

Publicaciones del Grupo de Anne Marie Caminade

Effect of viologen-phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities.
Ciepluch K, Weber M, Katir N, Caminade AM, El Kadib A, Klajnert B, Majoral JP, Bryszewska M.

Int J Biol Macromol. 2012 Dec 10;54C:119-124.

Organophosphorus chemistry for the synthesis of dendrimers.
Caminade AM, Laurent R, Zablocka M, Majoral JP.

Molecules. 2012 Nov 16;17(11):13605-21.

From graftable biphotonic chromophores to water-soluble organic nanodots for biophotonics: the importance of environmental effects.
Rouxel C, Charlot M, Mongin O, Krishna TR, Caminade AM, Majoral JP, Blanchard-Desce M.

Chemistry. 2012 Dec 14;18(51):16450-62.

Cytotoxicity and genotoxicity of cationic phosphorus-containing dendrimers.
Gomulak P, Klajnert B, Bryszewska M, Majoral JP, Caminade AM, Blasiak J.

Curr Med Chem. 2012 Dec 1;19(36):6233-40.

Validation of a generation 4 phosphorus-containing polycationic dendrimer for gene delivery against HIV-1.
Briz V, Serramía MJ, Madrid R, Hameau A, Caminade AM, Majoral JP, Muñoz-Fernández MA.

Curr Med Chem. 2012;19(29):5044-51.

Dendritic phosphoramidite ligands for Rh-catalyzed [2+2+2] cycloaddition reactions: unprecedented enhancement of enantiodiscrimination.
Garcia L, Roglans A, Laurent R, Majoral JP, Pla-Quintana A, Caminade AM.

Chem Commun (Camb). 2012 Sep 25;48(74):9248-50.

Organocatalysis with dendrimers.
Caminade AM, Ouali A, Keller M, Majoral JP.

Chem Soc Rev. 2012 Jun 7;41(11):4113-25.

DFT study of structure, IR and Raman spectra of the first generation dendron built from cyclotriphosphazene core with terminal carbamate and ester groups.
Furer VL, Vandyukov AE, Fuchs S, Majoral JP, Caminade AM, Kovalenko VI.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jun;91:97-105.

Phosphorus-containing dendrimers against α-synuclein fibril formation.
Milowska K, Gabryelak T, Bryszewska M, Caminade AM, Majoral JP.

Int J Biol Macromol. 2012 May 1;50(4):1138-43.

Synthesis of dye/fluorescent functionalized dendrons based on cyclotriphosphazene.
Hameau A, Fuchs S, Laurent R, Majoral JP, Caminade AM.

Beilstein J Org Chem. 2011;7:1577-83.

Biological properties of new viologen-phosphorus dendrimers.
Ciepluch K, Katir N, El Kadib A, Felczak A, Zawadzka K, Weber M, Klajnert B, Lisowska K, Caminade AM, Bousmina M, Bryszewska M, Majoral JP.

Mol Pharm. 2012 Mar 5;9(3):448-57.

Phosphorus dendrimers affect Alzheimer's (Abeta1-28) peptide and MAP-Tau protein aggregation.
Wasiak T, Ionov M, Nieznanski K, Nieznanska H, Klementieva O, Granell M, Cladera J, Majoral JP, Caminade AM, Klajnert B.

Mol Pharm. 2012 Mar 5;9(3):458-69.

Hierarchically porous nanostructures through phosphonate-metal alkoxide condensation and growth using functionalized dendrimeric building blocks.
Brahmi Y, Katir N, Hameau A, Essoumhi A, Essassi el M, Caminade AM, Bousmina M, Majoral JP, El Kadib A.

Chem Commun (Camb). 2011 Aug 14;47(30):8626-8.

Specific vapor sorption properties of phosphorus-containing dendrimers.
Gerasimov AV, Ziganshin MA, Vandyukov AE, Kovalenko VI, Gorbatchuk VV, Caminade AM, Majoral JP.

J Colloid Interface Sci. 2011 Aug 1;360(1):204-10.

A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis.
Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, Majoral JP, Eisenberg RA, Fournié JJ, Cantagrel A, Poupot R, Davignon JL.

Sci Transl Med. 2011 May 4;3(81):81ra35.

Nanostructuring polymeric materials by templating strategies.
Knoll W, Caminade AM, Char K, Duran H, Feng CL, Gitsas A, Kim DH, Lau A, Lazzara TD, Majoral JP, Steinhart M, Yameen B, Zhong XH.

Small. 2011 May 23;7(10):1384-91.

Vibrational spectra study of fluorescent dendrimers built from the cyclotriphosphazene core with terminal dansyl and carbamate groups.
Furer VL, Vandyukova II, Vandyukov AE, Fuchs S, Majoral JP, Caminade AM, Kovalenko VI.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Aug;79(3):462-70.

Fluorescent core-shell star polymers based bioassays for ultrasensitive DNA detection by surface plasmon fluorescence spectroscopy.
Feng CL, Yin M, Zhang D, Zhu S, Caminade AM, Majoral JP, Müllen K.

Macromol Rapid Commun. 2011 Apr 19;32(8):679-83.

Publicaciones del Grupo de Miguel López-Botet

CMV and Immunosenescence: from basics to clinics.
Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, et al.

Immun Ageing. 2012 Oct 31;9(1):23.

Functional impact of A91V mutation of the PRF1 perforin gene.
Martínez-Pomar N, Lanio N, Romo N, Lopez-Botet M, Matamoros N.

Hum Immunol. 2013 Jan;74(1):14-7.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.
Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66

The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope.
Shikhagaie M, Mercé-Maldonado E, Isern E, Muntasell A, Albà MM, López-Botet M, Hengel H, Angulo A.

J Virol. 2012 Apr;86(8):4091-101.

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.
Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M.

Clin Immunol. 2011 Dec;141(3):348-56.

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis.
Romo N, Fitó M, Gumá M, Sala J, García C, Ramos R, Muntasell A, Masiá R, Bruguera J, Subirana I, Vila J, de Groot E, Elosua R, Marrugat J, López-Botet M.

Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2314-21.

Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization.
Romo N, Magri G, Muntasell A, Heredia G, Baía D, Angulo A, Guma M, López-Botet M.

J Leukoc Biol. 2011 Oct;90(4):717-26.

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.
Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, Haahtela T, Lambrecht BN, Postma DS, Sunyer J, Valenta R,...Lopez-Botet M, et al.

Allergy. 2011 May;66(5):596-604.

Natural killer cell receptor expression reflects the role of human cytomegalovirus in the pathogenesis of a subset of CD4+ T-cell large granular lymphocytosis.
Sáez-Borderías A, Romo N, Ruiz-Cabello F, Cantón J, Tielemans D, Langerak AW, López-Botet M.

Hum Immunol. 2011 Mar;72(3):226-8

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.
Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, López-Botet M.

Blood. 2011 Jan 20;117(3):848-56

Publicaciones del Grupo de Jean François Rossi

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, Klein B.

Oncotarget. 2012 Nov;3(11):1335-47.

Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.

PLoS One. 2012;7(7):e42161.

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M.

Ann Oncol. 2012 Oct;23(10):2687-95.

Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
Auger S, Duny Y, Rossi JF, Quittet P.

Br J Haematol. 2012 Aug;158(3):386-98.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45.

Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia.
Rossi JF.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):136-8

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9

T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS, Klein B, Fiol G, Rossi JF.

Haematologica. 2011 Mar;96(3):400-7.

Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection.
Caraux A, Perez-Andres M, Larroque M, Requirand G, Lu ZY, Kanouni T, Rossi JF, Orfao A, Klein B.

Immunology. 2011 Feb;132(2):266-72.

Publicaciones del Grupo de Carlos Vilches

KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression.
Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C.

Front Immunol. 2012;3:289

Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860.
Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, Millán I, Cuervas-Mons V, Vilches C.

Transplantation. 2012 Aug 15;94(3):275-80.

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7.

KIR typing by non-sequencing methods: polymerase-chain reaction with sequence-specific primers.
Ordóñez D, Moraru M, Gómez-Lozano N, Cisneros E, Vilches C.

Methods Mol Biol. 2012;882:415-30.

Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity.
Moraru M, Cisneros E, Gómez-Lozano N, de Pablo R, Portero F, Cañizares M, Vaquero M, Roustán G, Millán I, López-Botet M, Vilches C.

J Immunol. 2012 May 1;188(9):4412-20.

Allele-specific amplification of the complete HLA-C gene from genomic DNA - a novel Cw4 allele (C*04:71) with a Cw1 motif in the peptide-binding site.
Moraru M, Balas A, de Pablo R, Vicario JL, Vilches C.

Tissue Antigens. 2012 Apr;79(4):291-4.

Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells.
Lorente E, Infantes S, Barnea E, Beer I, García R, Lasala F, Jiménez M, Vilches C, Lemonnier FA, Admon A, López D.

J Virol. 2012 Jan;86(1):527-41

Genetic basis of end-stage hypertrophic cardiomyopathy.
Garcia-Pavia P, Vázquez ME, Segovia J, Salas C, Avellana P, Gómez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L.

Eur J Heart Fail. 2011 Nov;13(11):1193-201

Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study.
Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, Vilches C, Bornstein B, Segovia J, Alonso-Pulpon L, Elliott PM.

Heart. 2011 Nov;97(21):1744-52

Mitochondrial haplogroups associated with end-stage heart failure and coronary allograft vasculopathy in heart transplant patients.
Gallardo ME, García-Pavía P, Chamorro R, Vázquez ME, Gómez-Bueno M, Millán I, Almoguera B, Domingo V, Segovia J, Vilches C, Alonso-Pulpón L, Garesse R, Bornstein B.

Eur Heart J. 2012 Feb;33(3):346-53.

Molecular characterisation of KIR2DS2*005, a fusion gene associated with a shortened KIR haplotype.
Ordóñez D, Gómez-Lozano N, Rosales L, Vilches C.

Genes Immun. 2011 Oct;12(7):544-51.

Publicaciones del Grupo de Martín Villalba

The protooncogene Vav1 regulates murine leukemia virus-induced T-cell leukemogenesis.
Kaminski S, Adjali O, Jacquet C, Garaude J, Keriel A, Lassaux A, Hipskind R, Sitbon M, Taylor N, Villalba M.

Oncoimmunology. 2012 Aug 1;1(5):600-608.

The NF-kappaB member p65 controls glutamine metabolism through miR-23a.
Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempé D, Lecellier CH, Villalba M.

Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56.

From tumor cell metabolism to tumor immune escape.
Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N.

Int J Biochem Cell Biol. 2013 Jan;45(1):106-13.